A B S T R A C T The effect of the microtubule inhibitor colchicine on the metabolism of 125I-low density lipoprotein (LDL) by cultured human skin fibroblasts and aortic medial cells was studied in vitro. Colchicine did not alter the binding of LDL to cell surface receptors. However, the rate of LDL endocytosis was reduced to 58% of that expected. Despite diminished endocytosis, LDL was found to accumulate within the cells to 165% of that expected, whereas the release of LDL protein degradation products into the medium was reduced to 34% of control, findings consistent with a reduced rate of intracellular LDL breakdown. Colchicine did not alter cell content of the acid protease which degrades LDL, nor did [3H]colchicine accumulate in lysosomal fractions. However, colchicine did alter the intracellular distribution of both fibroblast lysosomes and endosomes. After colchicine, lysosomes tended to accumulate in the perinuclear region, whereas endosomes were found at the cell periphery. These findings are consistent with the hypothesis that ingested LDL is less available to lysosomal enzymes in the presence of colchicine. The actions of colchicine appear to be a result of destruction of cell microtubules. Lumicolchicine, a mixture of colchicine isomers which (unlike the parent compound) does not bind to the subunit of microtubules, was without effect.
A B S T R A C T The effect of the microtubule inhibitor colchicine on the metabolism of 125I-low density lipoprotein (LDL) by cultured human skin fibroblasts and aortic medial cells was studied in vitro. Colchicine did not alter the binding of LDL to cell surface receptors. However, the rate of LDL endocytosis was reduced to 58% of that expected. Despite diminished endocytosis, LDL was found to accumulate within the cells to 165% of that expected, whereas the release of LDL protein degradation products into the medium was reduced to 34% of control, findings consistent with a reduced rate of intracellular LDL breakdown. Colchicine did not alter cell content of the acid protease which degrades LDL, nor did [3H]colchicine accumulate in lysosomal fractions. However, colchicine did alter the intracellular distribution of both fibroblast lysosomes and endosomes. After colchicine, lysosomes tended to accumulate in the perinuclear region, whereas endosomes were found at the cell periphery. These findings are consistent with the hypothesis that ingested LDL is less available to lysosomal enzymes in the presence of colchicine. The actions of colchicine appear to be a result of destruction of cell microtubules. Lumicolchicine, a mixture of colchicine isomers which (unlike the parent compound) does not bind to the subunit of microtubules, was without effect.
The uptake and degradation of LDL by cultured cells consists ofboth a receptor-specific component and nonspecific pinocytosis. Important differences must exist between these processes because even large amounts of LDL taken up and degraded by the nonspecific route fail to regulate key aspects of intracellular cholesterol metabolism. Colchicine selectively inhibited receptormediated LDL degradation. No effect was demonstrable on the nonspecific degradation of LDL by familial hypercholesterolemia fibroblasts grown in This paper was presented in part at the 1978 National Meeting of the American Federation for Clinical Research.
Received for publication 27 March 1.978 and in revisedformil 23 August 1978. medium containing serum and added sterols. The degradation of bovine albumin by normal cells was also unaffected. Colchicine sensitivity appears to be a biochemical marker for the LDL receptor-specific metabolic pathway.
Cytochalasins inhibit crosslinking and polymerization of cell microfilaments (although other important cell effects also occur). Cytochalasin D reduced LDL degradation to 44% of that expected. This result and the actions of colchicine suggest that cytoskeletal components such as microtubules and possibly microfilaments facilitate normal LDL metabolism.
INTRODUCTION
Low density lipoprotein (LDL)1 uptake and processing by cultured skin fibroblasts include several steps (1) . LDL binds to cell surface receptors and is internalized in small endocytic vesicles that fuse with lysosomes (2) . LDL is then degraded into free cholesterol and apoprotein fragments and the latter are released into the medium. There is reason to believe that cell microtubules and microfilaments might be involved in these processes.
Microtubules are 25-nm-diam, hollow core structures composed principally of tubulin (3) . They appear to be required for saltatory movement of fibroblast lysosomes (4) and may also regulate the fusion of lysosomes with endocytic vacuoles (6) (7) (8) and alter the mobility of plasma membrane receptors (9) . Tubulin is the only major cell protein that specifically binds colchicine (3, 5) . The binding of colchicine causes depolymerization of microtubules, making colchicine useful as a probe for microtubular function in cells. Endocytosis is inhibited by colchicine in several systems (10, 11) .
Microfilaments are morphologically quite distinct from microtubules. Composed principally of actin, they are 5-8 nm in diameter and may occur either in long bundles or in reticular networks (12) . Cytochalasins interfere with the filament crosslinking necessary to form cytoplasmic microfilament gels (13) and also disrupt microfilaments directly at high concentration (14) . The cytochalasins have other effects, however, including inhibition of glucose transport (15) . Microfilaments are thought to affect a variety of endocytic (10) and secretory processes (16) .
Because the interaction of LDL with cells involves endocytosis, we have studied the influence of colchicine and cytochalasins on LDL metabolism in cultured human skin fibroblasts and in aortic medial cells. We found that receptor-specific degradation of LDL was inhibited by colchicine, whereas nonspecific LDL degradation was not affected. Cytochalasin D also inhibited LDL degradation. Thus, "cytoskeletal" structures may importantly affect LDL metabolism. Lipoproteins. LDL of density 1.019-1.063 was prepared from normal donors, iodinated by the iodine monochloride technique to a specific activity of 228±21 (SEM) cpm/ng and diluted with native LDL to give a specific activity of -100 cpm/ng LDL protein (18) . All LDL additions were made as microgram per milliliter of LDL protein determined by the method of Sata et al. (19) . BSA was iodinated by the method of Hunter and Greenwood (20) and purified by chromatography over Sephadex G-100 (Pharmacia Fine Chemicals, Piscataway, N. J.).
METHODS
Cells. Normal fibroblasts were derived from skin explants taken from a 3-mo-old male, a 33-yr-old male, and a 40-yrold female. All normal lines gave similar results. Skin fibroblasts were also obtained from three patients with homozygous familial hypercholesterolemia. One is a 2-yr-old male who was classified as LDL "receptor-defective" on the basis of an LDL-induced:25-hydroxycholesterol-induced [14C]oleate incorporation ratio of 0.05:1, determined by published methods (21) . Cells from two LDL "receptor-negative" patients, a 12-yr-old female (GM 996) and a 13-yr-old female (GM 1915) were purchased from the Human Genetic Mutant Cell Repository, Camden, N. J. Aortic cells were derived from an explant of thoracic aortic media taken at autopsy from a 2Y2-mo-old male who died ofbronchopneumonia (26) . Cell culture was as previously described (18) . Fibroblasts were seeded at 75,000 per 35-mm-diam culture dish (or an equivalent amount for 60-100-mm dishes) and grown in 2 ml Eagle's Minimum Essential Medium (Gibco) containing 50 ,ug/ml streptomycin, 50 U/ml penicillin, 1.25 ,g/ml amphotericin B (Fungizone, Squibb Corp., New York), and 15% fetal bovine serum. After 72 h the medium was replaced and the cells were grown for another 72 h. The medium then was removed, the cells were washed with 1 ml Puck's saline G (22) , and 1 ml Eagle's Medium containing antibiotics, and 2.5 mg/ml human lipoprotein-deficient serum (18) was added. The cells were incubated 24 or 48 h before beginning an experiment. Aortic medial cells were grown similarly but in Dulbecco-modified Eagle's medium (Gibco) containing antibiotics, 15% fetal bovine serum, 1 mM sodium pyruvate, and 0.1 mM nonessential amino acids.
Cell 125I-LDL accumulation and degradation (18) . Cells were incubated at least 24 h in 5% lipoprotein-deficient human serum. The medium was removed and each 35-mm dish received 1 ml of fresh medium containing 5-500 ,ug/ml 125I-LDL. The cells were incubated at 37°C for 1-17 h after which the experiment was terminated by removal of the medium and placement of the cells at 40C. The cells were washed four times with 50 mM Tris-Cl, pH 7.4, in 0.15 M NaCl containing 2 mg/ml bovine albumin, and then twice with the preceding buffer without albumin. The cells were then dissolved in 0.1 N NaOH for determination of accumulated '25I-LDL. In some experiments the cell surface 125I-LDL was removed before dissolving the cells in NaOH by incubation for 1 h at 40C with 1 ml Puck's saline G containing 10 mg/ml heparin with pH corrected to 7.4 (23) . The saline G heparin was then aspirated and both it and cells, dissolved in 0.1 N NaOH, were counted separately. The noniodide 125j-LDL degradation products soluble in 10% trichloroacetic acid (TCA) were determined in the removed culture medium (18). 1 ml medium was added to 0.25 ml 50% TCA. After 30 min at 4°C the tubes were centrifuged at 1,000 g for 10 min and 1.0 ml of the supernate was removed and treated with 10 IlI 40% KI and 40 A1 30% H202 for 5 min at room temperature.
2 ml CHCI3 was added and the tubes were thoroughly vortexed after which 0.5 ml of the aqueous phase was counted. Blank dishes containing culture medium and '25I-LDL, but no cells, were routinely employed. Noniodide TCA soluble counts observed in blank dishes were subtracted from those of experimental dishes unless otherwise stated. Cell protein was determined by the method of Lowry et al. (24) . Statistical comparisons were performed by Student's t test. Means+SE of the mean are presented.
1251-LDL degradation by cell sonicates (25) . Five 100-mm dishes of normal fibroblasts were grown in the usual fashion including 24-h incubation in medium containing 2.5 mg/ml lipoprotein-deficient serum. The cells were washed and scraped into 15 ml 50-mM Tris-Cl, pH 7.4, containing 0.15 M NaCl. The cells were collected at 90 g for 3 min, washed in 5 ml of the same buffer, suspended in 0.75 ml water, and sonicated for 1.5 min on ice. Experiments were performed by incubating 20 ,ul of cell sonicate with 10 Al 1251-LDL containing -100,000 cpm (final concentration, 5 ,tg/ml) in 100 ,ul 0.1 M sodium acetate, pH 4.0, containing 5 mM dithiothreitol and 1 mM EDTA for 1 h at 37°C. 1251-LDL degradation products were then determined as described above.
Estimation of microtubules. An assay for microtubules in tissue culture cells is presented in detail elsewhere (36) . Fibroblasts were taken to a 37°C room and washed six times with 0.15 M NaCl. A 100-mm dish of cells was washed once (with 1 ml) and homogenized in 0.3 ml microtubule stabilization buffer consisting of 10 mM sodium phosphate (pH 6.95), 0.5 mM MgCl2, 0.5 mM guanosine 5'-triphosphate, 0.5 mM EGTA, 50% glycerol, and 5% dimethylsulfoxide, and placed at 4°C. Microtubules were separated from free tubulin by sedimentation of the former at 130,000 g for 10 min in a Beckman Airfuge (Beckman Instruments, Inc., Fullerton, Calif.). The microtubule-containing pellet was rehomogenized in 0.3 ml depolymerization buffer consisting of 0.25 M sucrose, 0.5 mM GTP, and 10 mM sodium phosphate, pH 6.95. After incubation at 4°C for 1 h, the solution containing depolymerized microtubule subunits was clarified by centrifugation at 130,000 g for 10 min. Colchicine binding activity of the supernate was determined by incubation at 37°C for 1 
RESULTS
Colchicine and LDL degradation. 125I-LDL metabolism was studied in human skin fibroblasts that had been previously treated with lipoprotein-deficient serum for 24 h to stimulate LDL uptake. 125I-LDL was added to control dishes and to dishes that had been preincubated for 2 h with 10 ,uM colchicine. Cellular degradation and accumulation of 125I-LDL were then observed in the presence and absence of colchicine for up to 6 h ( Fig. 1) . Colchicine significantly reduced 125I-LDL degradation at all time points, the average reduction being to 33.9±3.8% of the control value ( Fig.  IA ; P < 0.01). The accumulation of 125I-LDL by colchicine-treated cells was increased after the 1st h and at 6 h was 165±2.1% of control ( Fig. IB ; P < 0.01). In both control and colchicine-treated cells >94% of the accumulated radioactivity was precipitable in 15% TCA at 0°C.
Colchicine had similar effects in human aortic medial smooth muscle cells (Table I) . At 10 ,uM it reduced 1251-LDL degradation to 39% of control. A similar degree of inhibition of 1251-LDL degradation was noted in the presence of a 50-fold excess of unlabeled LDL. Accumulation of LDL was not significantly affected by colchicine.
A dose-response curve for the inhibition of 1251-LDL degradation in fibroblasts by colchicine is found in Fig.  2 . Normal fibroblasts were preincubated for 2 h with colchicine and also received colchicine during a 2-h incubation period with 1251-LDL. The lowest concentration of colchicine at which a significant reduction in LDL degradation occurred was 1 ,uM where 61+5.0% of the expected release of LDL degradation products occurred. But the addition of up to 100 ,uM colchicine caused no further decline in the release of degradation products. Lumicolchicine, a mixture of photochemical colchicine isomers which does not bind tubulin, had no significant effect upon 1251-LDL degra- dation at concentrations from 0.01 uM to 100 ,uM (Fig. 2) .
The effect of colchicine on fibroblast microtubule content was also studied (Fig. 2 ). Microtubules were reduced to 25% of expected levels by 0.1 ,M colchicine and to 4% by 1 ,M colchicine. Significant effects of colchicine on 125I-LDL degradation were noted at 1 ,uM and greater concentrations. Thus, the degradation of 125I-LDL was reduced only in the absence of significant numbers of microtubules. However, a significant proportion of 1251-LDL was degraded even in the absence ofdetectable microtubules at 10,M colchicine (Fig. 1) .
Effect of colchicine on nonspecific degradation. Fibroblasts from a normal subject and from patients with "receptor-defective" and "receptor-negative" hypercholesterolemia were tested for degradation of 1251-LDL in a single assay (Fig. 3) . Colchicine treatment (10 ,uM) reduced 1251-LDL degradation to 45% of that expected in normal cells, to 68% of that expected in LDL "receptor-defective" cells, and had no effect on "receptor-negative" cells. Because little LDL was degraded by cells deficient in receptors during a 2-h period, other experiments were performed (Table II) . Colchicine reduced 125I-LDL degradation to 52% of control during a 6-h incubation using normal fibroblasts in which LDL receptors had been induced by preincubation for 24-h in lipoprotein-deficient serum. (Table II) . Despite a 42% reduction in the degradation 1251-LDL in parallel dishes, no effect of colchicine was observed on 125I-BSA degradation.
Cytochalasin and LDL degradation. The effect of cytochalasins on LDL degradation is shown in Table   III . Cytochalasin D at 10 ,uM reduced 1251-LDL degradation to 44% of that expected. Similar to colchicine, the inhibition of degradation was not complete and even 100 ,uM cytochalasin D was no more effective than 1 ,uM. Cytochalasin B had no effect on LDL degradation at 10 ,uM (Table III) Three to five dishes per condition were preincubated for 24 h in either 5% lipoprotein-deficient serum (to induce LDL receptors) or in 15% fetal bovine serum containing 2 ,tg/ml 25-OH-cholesterol and 25 ,ug/ml cholesterol (to prevent induction of receptors). Dishes treated with colchicine received the drug in a small volume of water 2 h before as well as during the experiment. At time zero the medium of all dishes was replaced with Eagle's Medium + 5% lipoprotein-deficient serum containing tracer and the indicated drugs. Cells were incubated at 370C for 6 or 17 h. The amount ofapparent tracer degradation in dishes containing no cells was subtracted from all entries. * LPDS = Eagle's Medium + 5% lipoprotein-deficient human serum. 4 P < 0.001 with respect to no colchicine.
colchicine action in fibroblasts. Receptor-bound 1251_ LDL that had not yet been internalized was eluted into a solution of heparin, which is known to bind LDL (23) ( Table IV) . Colchicine at 10 AM had no significant effect upon heparin-releasable LDL. The rate of LDL internalization was next considered. This was estimated as the sum of 1251-LDL accumulation and degradation in Fig. 1 . At all time points, the rate of LDL uptake was significantly less in colchicinetreated cells, varying from 70% of that expected at 1 h to 58% at 6 h (P < 0.05). Hence, colchicine decreased the rate of LDL endocytosis. But at the same time the accumulation of 1251-LDL in colchicine-treated cells was always equal to or greater than that of controls (Fig.  1) . Because the heparin-elutable portion was unaffected by colchicine, this suggested that the rate of intracellular 1251-LDL processing must have been decreased to an even greater extent than the rate of endocytosis.
The possibility that colchicine inhibited the activity of enzyme(s) degrading LDL was tested. Colchicine inhibited 125I-LDL protein degradation in cell sonicates at very large concentrations (Table V ). An inhibition of only 22% occurred at 100 ,uM colchicine, whereas 1 AM was normally effective in our cell culture system (Fig. 2 ). However, it was possible that colchicine might have accumulated in lysosomes to sufficient concentration for inhibition of LDL degradation to occur during (Table VI) . Over 97% of the colchicine counts were found in the 130,000 g supernate, and very little colchicine was found in any particulate fractions. Thus, concentration of colchicine in lysosomes did not occur, confirming predictions based on its pK of 12.5 (27) . Therefore, direct inhibition of lysosomal enzymes could not have been a significant mechanism of colchicine action. Nor did colchicine affect the cell content of lysosomal LDL degrading enzymes. Fibroblasts were treated with 10 ,uM colchicine or a similar small amount of water for 4 h and then sonicated in water to release lysosomal enzymes. 1251-LDL degradation in the sonicates was 4,171+330 ng/mg protein per h in con- The degradation of 125I-LDL to TCA-soluble noniodide products by a fibroblast sonicate was determined at pH 4 as described in Methods. Each number represents the mean of three determinations. Basal 125I-LDL degradation was 17.2-20.2 ng/h. Normal fibroblasts were prepared as if for LDL binding by incubation in 5% lipoprotein-deficient serum for 24 h.
[3H]Colchicine at a final concentration of 1.0 ,uM, 536,900 cpm/ml, was added in a small volume and the cells were incubated at 370C for 3 h. They were then washed six times with 0.15 M NaCl and homogenized 100 strokes with a Teflonglass (DuPont Co., Wilmington, Del.) homogenizer in 0.3 ml 0.25 M sucrose containing 1 mM EDTA pH 7.0 and centrifuged at 500 g for 10 min. The pellet was washed with the same buffer and recentrifuged. The supernate was centrifuged at 130,000 g (average) for 10 min in a Beckman
Airfuge. The pellets were dissolved in 100 ,ul 1 N NaOH for counting. Numbers are the mean of two experiments.
trols and 4,103±228 ng/mg protein per h in colchicinetreated cells. Chloroquine, too, inhibited LDL degradation in cell sonicates at high concentration (Table V) . However, fibroblast lysosomes concentrate chloroquine to over 25 mM under conditions similar to ours (28) . The experiment of Table VII mechanism of action of chloroquine differed from that of colchicine. Cells were incubated with chloroquine alone, colchicine alone, or both drugs. Chloroquine increased 1251-LDL accumulation in cells to 215% of that expected. Colchicine also increased 251I-LDL accumulation slightly (but in this case not significantly). But when the drugs were added simultaneously, antagonism resulted such that the increased LDL accumulation seen with chloroquine was significantly reduced to control levels. In contrast, the effect ofthe two drugs to lower 1251I-LDL degradation was additive. This experiment suggested that colchicine increased fibroblast 125I-LDL accumulation by a different mechanism than chloroquine. The effect of colchicine occurred before lysosomal hydrolysis, the presumed site of chloroquine action. Because colchicine has been reported to alter the intracellular spatial orientation of cell organelles (5), the distribution pattern of lysosomes and LDL-containing endosomes was studied with and without colchicine treatment (Fig. 4) . Lysosomes visualized by supravital acridine orange staining (37, 38) were normally diffuse in cytoplasm, but tended to accumulate in the perinuclear region after colchicine (Fig.  4A, B) . LDL-containing endosomes, also diffuse in the cytoplasm of untreated cells, assumed a distinctly peripheral pattern after colchicine treatment when visualized by indirect immunofluorescence (41) (Fig.  4C, D) . Lumicolchicine 10 ,.tM had no effect on the distribution of either lysosomes or endosomes (results not shown).
DISCUSSION
Colchicine inhibited 125I-LDL degradation by cultured human fibroblasts and aortic medial cells to 35-55% of that expected. The effect appears to be a result of disaggregation of microtubules (Fig. 2 ). An amount of colchicine (1 ,uM) that resulted in disaggregation of 96% of the microtubules also inhibited 125I-LDL degradation. However, there was no effect on LDL degradation at 0.1 ,uM where microtubule disaggregation was 75% complete, suggesting that inhibition of 1251-LDL degradation required near total destruction of the microtubular cytoskeleton. Lumicolchicine (17) , a mixture of colchicine isomers that does not bind to the subunit protein of microtubules, had no effect on 1251. LDL degradation.
The pathway of LDL degradation by tissue culture cells involves several discrete steps (1) . LDL binds to a plasma membrane receptor which undergoes endocytosis in a vesicle. Fusion with lysosomes occurs after which LDL is hydrolyzed to free cholesterol and protein fragments in the secondary lysosome. We have studied the effect of colchicine on these processes.
The binding of 1251-LDL to its surface receptor was determined by heparin elution ofcell-associated counts (23) . Colchicine had no effect on receptor-bound LDL (Table IV) . However, the rate ofendocytosis, calculated as the sum of 1251-LDL cell accumulation and formation of 1251-protein degradation products, was reduced to 60% of that expected by colchicine (Table VII, Fig. 1 ). Despite a reduced rate of endocytosis, colchicine increased cell accumulation of 125I-LDL (Fig. 1B) . This required that colchicine reduce the effective rate of degradation of internalized 125I-LDL even more, either by reducing the fusion of endosomes with lysosomes or by directly inhibiting the activities or decreasing the amounts of the degrading enzymes.
There was no alteration in cell content of the lysosomal enzyme activity degrading LDL protein. Like- wise, colchicine did not accumulate in lysosomes in sufficient amount to inhibit the degradative enzymes directly (Tables V and VI) . The presence of adequate activities of degradative enzymes and of increased amounts of LDL in the cells suggested that colchicine produced a defect in endosome-lysosome fusion. This was supported by the altered distribution patterns of lysosomes stained with acridine orange (5, 37, 38) and LDL endosomes visualized by immunofluorescence (Fig. 4) . After colchicine treatment, lysosomes were found more prominently around the nucleus, whereas LDL endosomes were located more peripherally near the plasma membrane. Colchicine has been shown to inhibit endosome-lysosome fusion in several other cell types (6) (7) (8) and to stop the long saltatory movements of lysosomes in fibroblast-like cells (4) .
Degradation of 125I-LDL by cultured fibroblasts can occur after LDL uptake either by specific cell receptors or by nonspecific pinocytosis (1). The LDL receptors greatly increase LDL uptake and degradation at low LDL concentrations (5-10 ug/ml), and this results in regulation of intracellular cholesterol metabolism as manifested by increased esterification of cholesterol, decreased hydroxymethylglutaryl coenzyme A reductase activity, and fewer LDL receptors (1, 31) . How- ever, at high LDL concentrations (e.g., 200 ,ug/ml) the uptake and degradation of LDL by nonspecific pinocytosis may equal that mediated by receptors (18, 31) . But when LDL is taken up and degraded even in large amount by the nonspecific route, there is no regulation of cholesterol metabolism (31) . The biochemical basis of the difference between the specific and nonspecific "uptake pathways" is not known.
We have found that colchicine inhibited only specific receptor-mediated 1251-LDL degradation (Table II, Fig.  3 ). Colchicine had no effect on degradation of 125I-LDL taken up by nonspecific pinocytosis in receptor-negative cells treated with sterols, or in normal cells treated with sterols and assayed with a large concentration of 1251-LDL (500 ,ug/ml) to increase the relative amount of nonspecific uptake (Table II) . Colchicine had no effect (Table II) . Thus, colchicine sensitivity appears to be a biochemical marker for the receptor-specific pathway. This is consistent with published data demonstrating that uptake of small particles by pinocytosis is not sensitive to colchicine (32) .
The selective inhibitory effect of colchicine on receptor-specific LDL degradation could have several explanations. Receptor-LDL binding may serve to organize microtubules to assist in the uptake and degradation of the bound material. The binding of concanavalin A to the plasma membrane has resulted in the apparent polymerization, or at least redistribution, of microtubules to greater density near the binding site (34, 35) . Two types of endocytic vesicles have been identified in human skin fibroblasts (2) ; coated vesicles that contain the specific LDL receptors, and morphologically distinct, smaller, uncoated vesicles that do not contain LDL receptors but that are capable of nonspecific uptake of fluid from the cell exterior. It is possible that the preferential effect of colchicine on receptor-specific 125I-LDL degradation is because of an effect on the intracellular movement of the coated, but not the uncoated, vesicles. It is also possible that receptorspecific degradation of LDL occurs in specialized lysosomes and nonspecific degradation occurs in other lysosomes. For example, patients with ChediakHigashi syndrome demonstrate normal fusion of phosphatase-containing lysosomes with endocytic vesicles, but fusion of peroxidase and B-glucuronidasecontaining lysosomes is reduced (33) . This suggests that fusion of some, but not all, lysosomes with endosomes may be facilitated by microtubules. The possibility that nonspecific degradation might occur in the cytoplasm must also be kept in mind (39) , although published evidence indicates that nonspecific LDL degradation by familial hypercholesterolemia fibroblasts is highly chloroquine-sensitive and hence presumably occurs in lysosomes (40) .
Cytochalasin D, but not cytochalasin B, also inhibited '251-LDL degradation (Table III) . Cytochalasins have several effects upon cells (13) (14) (15) . However, the effect of cytochalasin D on LDL degradation could be a result of structural disorganization of actin-containing microfilaments, and the hypothesis that microfilaments are involved in cell LDL processing deserves further study. We believe that agents active against microtubules and microfilaments may be useful probes for further defining the LDL receptor pathway.
